Pfizer Inc. (PFE)

In the past six months, Pfizer Inc. stock price has experienced a 2.69% increase. In December 2025, Pfizer's share price fell by 5% due to projected revenue decline from COVID-19 products and loss of exclusivity for some products. On September 30, 2025, Pfizer secured a $70 billion deal with President Trump to boost R&D and domestic production, including a three-year tariff exemption. Pfizer acquired Metsera Inc. in November 2025 to advance its pipeline in GLP-1 drugs, with launches targeted by 2028. Positive results from the BREAKWATER trial were announced in January 2026, and Pfizer is pursuing a priority review voucher from the FDA.

The demand for Pfizer's products and services exhibits some seasonality, particularly concerning vaccines and treatments for infectious diseases. The utilization of Paxlovid is directly related to COVID infection rates. Sales of the Prevnar franchise saw an 18% year-over-year increase internationally but declined by 12% domestically in the U.S. Comirnaty experienced a 9% sales increase internationally but a 25% decline in the U.S. Historically, prescription drugs and vaccines account for the majority of Pfizer's sales.

Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, founded in 1849. It is a research-based biopharmaceutical company involved in the discovery, development, manufacture, marketing, sale, and distribution of medicines and vaccines globally, operating within the healthcare sector, specifically in the pharmaceutical and biotechnology industries. Pfizer's product portfolio addresses a wide range of therapeutic areas, including immunology, oncology, cardiology, endocrinology, neurology, anti-infectives, diabetes, obesity, inflammation, rare diseases, and bacterial infections. Major products include Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance, along with other significant brands and treatments.

Pfizer Inc. has a significant global presence, operating in the United States, Developed Markets, and Emerging Markets. The company distributes its products through wholesalers, retailers, and government agencies. Pfizer maintains manufacturing units in numerous countries worldwide, including Belgium, Germany, India, Ireland, Italy, Japan, Singapore, and the United States.

Pfizer's brand reputation experienced a significant boost during the COVID-19 pandemic, with more favorable reporting on the pharmaceutical industry. Pfizer's reputation improved after announcing its vaccine's high efficacy rate in November 2020, and the company introduced a new logo in January 2021. However, Pfizer's reputation scores, along with those of other major COVID vaccine makers, dropped to pre-COVID levels in 2022 due to a shift in public support and the rise of misinformation surrounding COVID shots.

Pfizer Inc. is primarily owned by institutional shareholders, who hold 63.56% of the company's stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual/insider shareholders hold approximately 0.27% of Pfizer's shares, with the top individual/insider shareholders being Albert Bourla, Mikael Dolsten, and Douglas Lankler.